Cargando…

Incorporating adjustments for variability in control group response rates in network meta-analysis: a case study of biologics for rheumatoid arthritis

BACKGROUND: The importance of adjusting for cross-study heterogeneity in control group response rates when conducting network meta-analyses (NMA) was demonstrated using a case study involving a comparison of biologics for the treatment of moderate-to-severe rheumatoid arthritis. METHODS: Bayesian NM...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cameron, Chris, Varu, Abhishek, Lau, Arthur, Gharaibeh, Mahdi, Paulino, Marcelo, Rogoza, Raina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6796442/ https://www.ncbi.nlm.nih.gov/pubmed/31619175 http://dx.doi.org/10.1186/s12874-019-0837-2

Ejemplares similares

Incorporating the Treat-to-Target Concept in Rheumatoid Arthritis
por: Ruderman, Eric M., et al.
Publicado: (2012)

Systematic review and network meta-analysis comparing palbociclib with chemotherapy agents for the treatment of postmenopausal women with HR-positive and HER2-negative advanced/metastatic breast cancer
por: Wilson, Florence R., et al.
Publicado: (2017)

Treatment Patterns and Costs in Biologic DMARD-Naive Patients with Rheumatoid Arthritis Initiating Etanercept or Adalimumab with or Without Methotrexate
por: Tkacz, Joseph, et al.
Publicado: (2020)

Effectiveness and Costs Among Rheumatoid Arthritis Patients Treated with Targeted Immunomodulators Using Real-World U.S. Data
por: Gharaibeh, Mahdi, et al.
Publicado: (2020)

Assessing the Association of Formulary Copayment Changes with Real-World Treatment Patterns in Patients with Rheumatoid Arthritis on Etanercept
por: Bonafede, Machaon, et al.
Publicado: (2020)

The efficiency of biologic therapy in a group of patients with rheumatoid arthritis
por: Gavrilă, BI, et al.
Publicado: (2015)

Adjusting for sex and anti-CCP levels in linkage analysis of rheumatoid arthritis
por: Lebrec, Jérémie JP, et al.
Publicado: (2007)

Treatment patterns in rheumatoid arthritis patients newly initiated on biologic and conventional synthetic disease-modifying antirheumatic drug therapy and enrolled in a North American clinical registry
por: Mease, Philip J., et al.
Publicado: (2021)

Incorporating multiple-marker information to detect risk loci for rheumatoid arthritis
por: Wang, Xuexia, et al.
Publicado: (2009)

The Effect of Dose Escalation on the Cost-Effectiveness of Etanercept and Adalimumab with Methotrexate Among Patients with Moderate to Severe Rheumatoid Arthritis
por: Incerti, Devin, et al.
Publicado: (2020)

Intestinal Amyloidosis in Common Variable Immunodeficiency and Rheumatoid Arthritis
por: Meira, T., et al.
Publicado: (2015)

Disease activity and biologic use in patients with psoriatic arthritis or rheumatoid arthritis
por: Kavanaugh, Arthur, et al.
Publicado: (2018)

Commentary: Corneal involvement in rheumatoid arthritis
por: Acharya, Manisha, et al.
Publicado: (2021)

Variability in synovial inflammation in rheumatoid arthritis investigated by microarray technology
por: Lindberg, Johan, et al.
Publicado: (2006)

Within-subject foot motion variability in patients with Rheumatoid Arthritis
por: Hooper, Lindsey, et al.
Publicado: (2010)

Personalization of biologic therapy in patients with rheumatoid arthritis: less frequently accounted choice-driving variables
por: Niccoli, Laura, et al.
Publicado: (2018)

Outcomes and costs of incorporating a multibiomarker disease activity test in the management of patients with rheumatoid arthritis
por: Michaud, Kaleb, et al.
Publicado: (2015)

Pattern of Young and Old Onset Rheumatoid Arthritis (YORA and EORA) Among a Group of Egyptian Patients with Rheumatoid Arthritis
por: El-Labban, Abdou S., et al.
Publicado: (2010)

Circulating VEGF As a Biological Marker in Patients with Rheumatoid Arthritis? Preanalytical and Biological Variability in Healthy Persons and in Patients
por: Hetland, Merete Lund, et al.
Publicado: (2008)

The onset of rheumatoid arthritis following trauma
por: Brawer, Arthur E, et al.
Publicado: (2016)

Biologic agents for rheumatoid arthritis—negotiating the NICE technology appraisals
por: Kiely, Patrick D. W., et al.
Publicado: (2012)

Increased DNA methylation variability in rheumatoid arthritis-discordant monozygotic twins
por: Webster, Amy P., et al.
Publicado: (2018)

Herceptin® (trastuzumab) in HER2-positive early breast cancer: a systematic review and cumulative network meta-analysis
por: Wilson, Florence R., et al.
Publicado: (2018)

Biologic monotherapy in the treatment of rheumatoid arthritis
por: Detert, Jacqueline, et al.
Publicado: (2015)

Biologicals in rheumatoid arthritis: current and future
por: Avci, Ali Berkant, et al.
Publicado: (2015)

Treatment with Biologicals in Rheumatoid Arthritis: An Overview
por: Rein, Philipp, et al.
Publicado: (2017)

Usefulness of Patients-Reported Outcomes in Rheumatoid Arthritis Focus Group
por: Amaya-Amaya, Jenny, et al.
Publicado: (2012)

ABO and Rh blood groups in patients with lupus and rheumatoid arthritis
por: Nik, Amir, et al.
Publicado: (2021)

Biologic refractory disease in rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
por: Kearsley-Fleet, Lianne, et al.
Publicado: (2018)

Adjustment of the multi-biomarker disease activity score to account for age, sex and adiposity in patients with rheumatoid arthritis
por: Curtis, Jeffrey R, et al.
Publicado: (2019)

Dose Adjustment of Methotrexate Administered Concomitantly with Golimumab for Rheumatoid Arthritis in Japanese Real-World Clinical Settings
por: Yamairi, Fumiko, et al.
Publicado: (2020)

A Matching-Adjusted Indirect Comparison of Upadacitinib Versus Tofacitinib in Adults with Moderate-to-Severe Rheumatoid Arthritis
por: Edwards, Christopher J., et al.
Publicado: (2020)

Frequency, Predictors, and Economic Impact of Upward Dose Adjustment of Infliximab in Managed Care Patients With Rheumatoid Arthritis
por: Ollendorf, Daniel A., et al.
Publicado: (2005)

EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis
por: Gerlag, Danielle M, et al.
Publicado: (2012)

Association mapping of susceptibility loci for rheumatoid arthritis
por: Kuo, Tai-Yue, et al.
Publicado: (2007)

The Differential Diagnosis of Gout, Rheumatism, and Rheumatoid Arthritis
por: Luff, Arthur P.
Publicado: (1900)

Dual Biologic Therapy in Patients with Rheumatoid Arthritis and Psoriatic Arthritis
por: Furer, Victoria, et al.
Publicado: (2023)

Down-titration of biologics for the treatment of rheumatoid arthritis: a systematic literature review
por: Lau, Chak Sing, et al.
Publicado: (2017)

Interleukin-6 inhibitors in the treatment of rheumatoid arthritis
por: Hennigan, Stephanie, et al.
Publicado: (2008)

TH-17 cells in rheumatoid arthritis
por: Shahrara, Shiva, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_cut6s38qlia7agconkt6ddrva6